Market Update (NASDAQ:GILD): Gilead leukemia drug trial unblinded early due to success

[Reuters] – A late stage trial of a Gilead Sciences drug in previously treated patients with a particular type of leukemia was unblinded early after independent monitors determined the medicine provided significant benefit . . . → Read More: Market Update (NASDAQ:GILD): Gilead leukemia drug trial unblinded early due to success Similar Articles: Company Update (NASDAQ:GILD): FDA approves Gilead Sciences’ HIV drug cocktail Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead’s new HIV drug shows lower side-effects over longer term Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead combo drug fights all genotypes of hep C infection: data